The full report can be found here https://goo.gl/hshRvl Wearables will change the execution and economics of drug R&D, expand the definition of “therapy,” and transform patients’ roles in healthcare. Wearable technologies have the potential to transform medicine and the delivery of healthcare more significantly than any other component of the digital revolution – or indeed than many other scientific advances. By offering new, richer, and more nuanced sources of real-time data directly from patients, wearables can enable a greater understanding of disease and the factors that influence its course, both at the individual level and collectively. Wearables will transform how clinical trials are recruited and run, and which kinds of endpoints are measured. They will also change the economics of R&D, allowing faster recruitment, more reliable data collection, and shorter trial times. For pharma, wearables provide not just an opportunity to reduce R&D costs, but also to improve outcomes and enhance relationships with patients, providers, and payers. They also bring new kinds of partners and competitors, and require a shift in mindset: to accept that future winners will not be those with the best molecule, but those who most effectively marry their scientific innovation with the appropriate technological innovation to ensure the best results. The full report can be found here https://goo.gl/hshRvl

1. Report Extract

2. Trends Hot Topic DMKC0160959 | Published on 06/06/2016
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
2
Report reference: DMKC0160959
Published on: 06/06/2016
About Datamonitor Healthcare
Complete market coverage
Our independent research and analysis provides extensive coverage of major disease areas,
companies and strategic issues, giving you the perspective to identify opportunities and
threats arising from shifting market dynamics and the insights to respond with faster, more
effective decision-making.
Unique expert capabilities
With teams located across developed and emerging pharma markets, we are uniquely placed to
understand local healthcare trends and provide accurate and reliable recommendations. By
working closely with our partners at MedTrack,Citeline, SCRIP Intelligence and Informa
Healthcare, our experts are able to share data and resources to produce the most
authoritative and robust market intelligence. With over 700 clients across the pharma and
biotech industries, we are relied upon to provide strategic guidance, not only through published
analysis, but also tailored support solutions.
Cutting-edge delivery
Available through single reports or via subscription to our state-of-the art online intelligence
service that features intuitive design and interactive capabilities, our analysis offers the
definitive platform to enhance your product management, market assessment and strategic
planning.
Additional Strategy Series Reports:
Bringing you a clearer, richer and more responsive view of the pharma & healthcare market.
- Profitability Assessment of Branded Generic Inhalers
- Immuno-Oncology Deal Trends, 2011–15
- Big Pharma Licensing Trends, 2011–15
- Pharma's Patient Centricity
- Psoriatic Arthritis Pricing, Reimbursement, and Access
- COPD Pricing, Reimbursement, and Access
- Multiple Myeloma Pricing, Reimbursement, and Access
- Asthma Pricing, Reimbursement, and Access
- Hepatitis C Pricing and Reimbursement
- Malignant Melanoma Pricing and Reimbursement
- Access in Emerging Markets: HTA is Making Inroads
- CER, HEOR, and Value-Based Frameworks in the US
- Key Trends in European Market Access
- Biosimilars Market Access in the US
- Oncology Pathways in the US – Friend or Foe for Pharma?
- Accountable Care Organizations: What Impact on Pharma?
- EGA Biosimilars Conference 2015
- Beyond-the-Pill Services and Solutions: Pharma’s Next Frontier?

3. Trends Hot Topic DMKC0160959 | Published on 06/06/2016
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
3
CONTENTS
5
5
5
5
5
5
5
EXECUTIVE SUMMARY
What are wearables, and why should pharma care?
Wearables makers: pharma partners or competitors?
Wearables’ early impact in R&D and beyond
Drivers and resistors of wearables in healthcare
Case studies involve a range of players, devices, and therapy
areas Wearables are part of digital health investments
7
9
9
10
WHAT ARE WEARABLES, AND WHY SHOULD PHARMA CARE?
Wellness and medicine: blurring boundaries
Enabling patient centricity; lowering costs
Bibliography
12
12
16
17
WEARABLES MAKERS: PHARMA PARTNERS OR
COMPETITORS?Who is making wearables?
Fostering and funding digital health innovation
Bibliography
20
20
25
WEARABLES’ EARLY IMPACT IN R&D AND BEYOND
Most wearables trials to date have been feasibility
studies Bibliography
28
28
31
33
DRIVERS AND RESISTORS OF WEARABLES IN HEALTHCARE
Drivers
Resistors
Bibliography
36
36
39
40
40
41
41
42
43
43
44
44
WEARABLES CASE STUDIES
Wearables are used along the value chain and across stakeholders
Biogen-Google: uncovering the course of multiple sclerosis
Novartis-Qualcomm: building the foundations for mobile trials
Novartis-Microsoft: measuring multiple sclerosis
UCB-MC10: improving diagnosis and treatment of Parkinson’s disease
Johns Hopkins-Apple: using Apple Watch to predict seizures
UnitedHealthcare-Qualcomm: paying for steps
Medibio-Medtronic: diagnosing depression
Google (Verily)-Dexcom: stick-on glucose monitors for diabetes
Otsuka-Proteus Digital Health: digital medicines may improve outcomes but first
must pass regulatory muster
Bibliography
48
48
WEARABLES ARE PART OF DIGITAL HEALTH INVESTMENTS
Unquantified investments

4. Trends Hot Topic DMKC0160959 | Published on 06/06/2016
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
4
LIST OF FIGURES
LIST OF TABLES
48
49
52
53
Efficacy gains expected
Who will pay for wearables in healthcare?
The technological future
Bibliography
55
55
55
55
APPENDIX
About theauthor
Scope
Methodology
8
50
50
51
Figure 1: Wearables’ impact on drug development and marketing
Figure 2: Return on investment from wearables may be realized by supporting higher
reimbursement
Figure 3: Patients’ out-of-pocket purchases of wearables could also feature in future
business models
Figure 4: Wearables can also benefit the bottom line by improving R&D efficiency
12
14
28
37
Table 1: Makers of wearables
Table 2: Examples of pharma’s partnerships involving wearables
Table 3: Drivers and resistors of use of wearables in healthcare
Table 4: Selected case studies of wearables’ use

5. Trends Hot Topic DMKC0160959 | Published on 06/06/2016
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
9
Wellness and medicine: blurring boundaries
For now, wearables remain in the experimental phase in regulated medicine. However, the
rapid uptake of health-related wearables such as Fitbit or Jawbone activity trackers within the
consumer market provides a glimpse of the potential of such devices in healthcare. That
opportunity has not escaped the attention of technology and software firms, from giants like
Google to tiny start-ups.
Indeed, the boundary between tools to enable healthy lifestyles and therapeutic solutions to
optimize health outcomes is blurring. Most of the recognized wearable brands, like Fitbit or
Garmin, are marketing device-enabled corporate wellness programs to employers seeking to
lower their health insurance costs (Garmin, 2016). A few healthcare providers, meanwhile,
have started to use devices like Withings’ Wireless Blood Pressure Monitor, a cuff which
connects wirelessly to a smartphone to allow patients to easily take and monitor their own
readings at home, and/or to subsequently share them with a physician (Stanford, 2014). The
device has US Food and Drug Administration (FDA) and European device clearance, and can be
purchased online, along with the rest of Withings’ suite of consumer-tech products. Even
payers are getting in on the action: UnitedHealthcare is offering free activity tracker devices to
some employers and employees, allowing them to earn dollar credits off their insurance
premiums by moving more each day (UnitedHealthcare, 2016).
Enabling patient centricity; lowering costs
As well as expanding the boundaries of modern medicine, wearables are also turning medicine
on its head by putting patients, rather than physicians, at the center. Patients are increasingly
generating their own data, and thereby becoming far more empowered guardians of their own
health, and more
Figure 1: Wearables’ impact on drug development and marketing
Source: Datamonitor Healthcare

6. Trends Hot Topic DMKC0160959 | Published on 06/06/2016
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
29
Drivers
TECHNOLOGICAL: RAPIDLY INCREASING DEVICE SOPHISTICATION; BETTER DATA
ANALYTICS, ENCRYPTION, AND STORAGE CAPABILITIES
In just seven years since the first Fitbit activity tracker was launched, both consumer-focused
and medical-grade wearables have become hugely more sensitive, sophisticated, discreet,
and reliable. They underpin the “quantified self” movement that puts consumers in control of
their own health and wellbeing by allowing them to track various physiological and
psychological parameters in real time. Greater connectivity means that patients can also more
easily and conveniently access specialist advice, armed with real-time data on health
variables. Advances in data analytics techniques and platforms (across a wide range of data
sources, including for instance Internet/social media data), secure storage capabilities and
encryption, and software solutions offering device interoperability are enabling the greater use
of and reliance on wearable tools. Moreover, the body-technology boundary is blurring as
wearables miniaturize (thanks to advances in semiconductors, connectivity, and battery life) into
skin-like patches or “BioStamps,” tiny subdermal implants, and ingestibles (Sheynin, 2016).
COMPETITIVE AND ECONOMIC: DRIVE TOWARDS IMPROVED, MORE COST-EFFECTIVE OUTCOMES
The 2010 Affordable Care Act in the US has compelled payers and providers to focus on cost-
effective care delivery and improved outcomes. Wearable technologies can help with both, in
particular for patients suffering from chronic conditions.
By allowing patients’ conditions to be monitored and assessed within the home
environment, wearables can help avoid emergency care and hospitalization, as well as making
care more convenient for the patient, for example by linking to apps or online programs offering
support and tailored advice. Wearables and related mobile technologies can help increase
medication compliance – a huge driver of outcomes – without sacrificing care quality or
personalization: indeed, real-time data sources can improve personalization.
MORE EFFICIENT R&D, BETTER DIFFERENTIATED MEDICINES
Pharma faces pricing pressure across both specialist and chronic indications. This demands
more efficient R&D, and more clearly differentiated medicines with demonstrably good
outcomes. Wearables can help at all stages of R&D, but also in future as part of
commercial therapies.
Wearables offer the potential to accelerate trial recruitment and shorten trial times (through
greater retention rates), thus lowering R&D costs. In some chronic diseases, they may also
form part of the on-market product differentiation required to resist commoditizing prices: in
diabetes, a lack of significant therapeutic innovation means the competition comes down
to which devices and technology systems can show improved outcomes. Even in specialist
areas like cancer, competition and payer pushback are forcing pharma to prove outcomes and
control prices.
The use of wearable tools in R&D is moving downstream from early development as data
are generated and confidence builds. As with any new endpoint, or measures such as
biomarkers, “those measurements that work will move forward with medicine through its
development lifecycle,” notes

7. Trends Hot Topic DMKC0160959 | Published on 06/06/2016
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
52
The technological future
Wearables will evolve to become smaller, more robust, and more powerful. To overcome the
problem of getting users to engage over the long term, they will become frictionless – requiring
little or no active input from the wearer, instead automatically uploading information to send to
the doctor. “The less amount of time a user has to actively do something to get data, the more
they’ll use it,” explains Rick Rudick, Biogen’s vice president of development sciences and head of
value based medicines. “If I have to take off a sensor, plug it in, upload it, and answer questions,
I’ll soon get tired,” he says, citing experience (personal correspondence, 2016e). Many wearables
may transition into “insideables,” worn under the skin. The tools and algorithms used to analyze
and make meaning from wearables data will also evolve, perhaps eventually to become self-
learning, using data from across ever larger samples and treatments to start to predict the
course of a disease, for instance.
Figure 4: Wearables can also benefit the bottom line by improving R&D efficiency
Source: Datamonitor Healthcare

8. Datamonitor Healthcare
Pharma intelligence |
The best coverage.
The best forecasts.
The best analysts.
The best support.
The Best of Health.
Introducing The New Datamonitor Healthcare.
We’ve quadrupled our business intelligence which covers more than 90% of prescription
medicines in the major markets. Our forecasts are tailored to your needs as events occur
and are powered by a new forecasting tool built in collaboration with a leading analytics
technology provider. We’ve increased our global analyst resources by 300%, and Live
Support replies to your queries in real time, not hours, for the fastest support in the
market.
We’ve just made strategic investments in
Datamonitor Healthcare to give you the best of health.
Discover the best of health.
Visit www.BestofHealthDatamonitor.com to tour the new Datamonitor Healthcare with one of our representatives.
Request a live demo and see how The Best of Health supports smarter, faster decision-making.